文献速递临床试验与 GCP

肠易激综合征开放标签与双盲安慰剂治疗的比较:一项随机对照试验的研究方案

Open-label versus double-blind placebo treatment in irritable bowel syndrome: study protocol for a randomized controlled trial.
PubMed 文献 · Trials · 2017-05-25

该研究为一项多学科随机对照试验方案(n=280),旨在重复并扩展既往肠易激综合征开放标签安慰剂研究。研究将开放标签安慰剂与双盲安慰剂进行比较,后者通过嵌套的双盲随机对照试验(比较双盲安慰剂与薄荷油)实现。研究还探讨开放标签安慰剂可能的遗传与心理预测因素,并通过访谈了解参与者体验。

要点

  • 开放标签安慰剂可诚实告知为安慰剂,仍可能改善肠易激综合征症状。
  • 研究首次直接比较开放标签安慰剂与双盲安慰剂的给药效果。
  • 试验同时探索开放标签安慰剂的遗传、心理及体验维度预测因素。

核心结论

  • 开放标签安慰剂治疗是一种在伦理上利用安慰剂效应的新策略,可能重塑安慰剂理论并影响医生优化对常见主观症状的观察等待策略。
  • 本研究旨在通过首次比较开放标签与双盲安慰剂给药,大幅扩展对开放标签安慰剂的认知。

研究设计与样本

  • 本研究为多学科随机对照试验方案,计划样本量n=280。
  • 研究将开放标签安慰剂与双盲安慰剂进行比较,后者通过嵌套的双盲随机对照试验(比较双盲安慰剂与薄荷油)实现。
  • 研究通过一系列对随机选取亚组的深入访谈,考察开放标签安慰剂和双盲安慰剂的参与者体验。

主要发现

  • 近期多项随机对照试验(包括肠易激综合征、慢性腰背痛和发作性偏头痛患者)表明,接受开放标签安慰剂的个体仍可经历症状改善并从诚实描述的安慰剂治疗中获益。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Placebo medications, by definition, are composed of inactive ingredients that have no physiological effect on symptoms. Nonetheless, administration of placebo in randomized controlled trials (RCTs) and in clinical settings has been demonstrated to have significant impact on many physical and psychological complaints. Until recently, conventional wisdom has suggested that patients must believe that placebo pills actually contain (or, at least, might possibly contain) active medication in order to elicit a response to placebo. However, several recent RCTs, including patients with irritable bowel syndrome (IBS), chronic low back pain, and episodic migraine, have demonstrated that individuals receiving open-label placebo (OLP) can still experience symptomatic improvement and benefit from honestly described placebo treatment. METHODS AND DESIGN: This paper describes an innovative multidisciplinary trial design (n = 280) that attempts to replicate and expand upon an earlier IBS OLP study. The current study will compare OLP to double-blind placebo (DBP) administration which is made possible by including a nested, double-blind RCT comparing DBP and peppermint oil. The study also examines possible genetic and psychological predictors of OLP and seeks to better understand participants' experiences with OLP and DBP through a series of extensive interviews with a randomly selected subgroup. DISCUSSION: OLP treatment is a novel strategy for ethically harnessing placebo effects. It has potential to re-frame theories of placebo and to influence how physicians can optimize watch-and-wait strategies for common, subjective symptoms. The current study aims to dramatically expand what we know about OLP by comparing, for the first time, OLP and DBP administration. Adopting a unique, multidisciplinary approach, the study also explores genetic, psychological and experiential dimensions of OLP. The paper ends with an extensive discussion of the "culture" of the trial as well as potential mechanisms of OLP and ethical implications. TRIAL REGISTRATION: ClinicalTrials.gov, identifier: NCT02802241 . Registered on 14 June 2016.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Ballou S, Kaptchuk TJ, Hirsch W, et al. Open-label versus double-blind placebo treatment in irritable bowel syndrome: study protocol for a randomized controlled trial. Trials. 2017. PMID: 28545508. doi:10.1186/s13063-017-1964-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。